Table 4.
Modifications of PLGA nanoparticles for vaccine delivery.
| Disease | Antigen | Immuno-Adjuvant | Modification | Ref. |
|---|---|---|---|---|
| Cancer (Melanoma) | Melan-A:26 , gp100:209 (peptides). OVA as model antigen. | Poly (I:C), CpG | Mannose functionalized delivery system (PLGA, PEG-PLGA and Mannose-PEG-PCL) was developed to target CD206/MR on DC. | [96] |
| MART-1 (peptide) | - | Biotinylated anti-human DEC-205 monoclonal antibodies were used to target DCs. | [97] | |
| Cancer | OVA as model protein antigen | Pam3Csk4, Poly (I:C) | Agonistic α-CD40-mAb were conjugated on the surface of PLGA nanoparticles for CD-40 targeted DC delivery. | [98] |
| Cancer cell membrane obtained from mouse-melanoma cells | - | PLGA nanoparticle were coated with cancer cell membrane to introduce multiple surface antigen which is challenging with traditional synthetic methods. | [99] | |
| OVA as model protein antigen along with SOCS1 siRNA | - | Silencing of immunosuppressive SOCS1 gene augmented pro-inflammatory cytokine response. | [100] | |
| Improved Hybrid polymer-lipid particle | BSA | - | Cholesterol coated PLGA particle showed improved stability with better cellular uptake and more controlled antigen release. | [101] |
| Malaria | Pfs25 (Plasmodium falciparum Transmission-Blocking Antigen) | - | - | [102] |
| VMP001 | MPLA | Lipid (DOPC, DOPG, mal-PE) coated PLGA particles were developed with surface presentation of antigen using maleimide-thiol conjugation. | [103] |